Oxygen Biotherapeutics (OXBT) reported last Tuesday, June 18th, that it had completed preclinical trials on animals evaluating its lead drug candidate, Oxycyte, for potential effects on the body's immune system. Oxycyte® is a perfluorocarbon-based intravenous oxygen carrier with multiple potential uses. Lead trials are focusing on the ability of the treatment to rapidly deliver oxygen to the patient's brain after a traumatic brain injury (TBI) to reduce acute damage and long-term complications. While news came out on the 18th, the company's stock action has been gradually responding with increasing liquidity and share price, although the overall markets have put a drag on share price this week. With a split-adjusted 52-week range of $2.53-$34.40, I believe...
Oxygen Biotherapeutics Makes Recent Progress In An Under-Met Indication
Jun 28 2013, 15:16 | about: OXBT
BOOKMARKED / READ LATER
Added to your bookmarks on the Seeking Alpha homepage